LOGIN  |  REGISTER
Recursion

Streamline Health Announces New eValuator™ Contract With Texas-Based Health System

November 05, 2024 | Last Trade: US$2.33 0.02 0.87

ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that is has signed a new contract for the use of eValuator with a 900-bed, Altera EHR-based health system serving northern Texas. This marks the fourth Texas health system to adopt eValuator, reinforcing Streamline Health’s growing presence in the region.

Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. eValuator’s AI-enhance pre-bill code auditing ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide while avoiding denials.

“Texas plays a pivotal role in our nation’s healthcare landscape and we are proud to expand our footprint there,” stated Ben Stilwill, Chief Executive Officer. “Our team is excited to help another of our nation’s health systems ensure they are accurately paid for the care they’ve provided.”

About Streamline Health

Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page